



## Pataday® (olopatadine) – First-time Generic

- On June 9, 2017, Teva launched its AT-rated generic version of Alcon Laboratories' Pataday (olopatadine) 0.2% ophthalmic solution, for the treatment of ocular itching associated with allergic conjunctivitis.
- Olopatadine is also available as 0.1% and 0.7% ophthalmic solutions and as a nasal spray. The 0.1% ophthalmic solution and the nasal spray are generically available.
- According to IMS Health, the U.S. market for Pataday is approximately \$303 million.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.